Related Experiment Video
Updated: Aug 10, 2025
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.5K
Opioid Use in Patients With Inflammatory Bowel Disease
Xiwu Lin1, Jennifer Lofland2, Ling Zhang1
1Quantitative Sciences, Janssen Pharmaceutical Research & Development, LLC., Spring House, Pennsylvania, USA.
Crohn'S & Colitis 360
|February 13, 2023
Summary
Opioid use is more common in inflammatory bowel disease (IBD) patients. Opioid users with IBD face higher risks of hospitalizations and emergency room visits, indicating potential disease undertreatment.
Area of Science:
- Gastroenterology
- Pharmacology
- Health Services Research
Background:
- Limited data exists on opioid utilization in inflammatory bowel disease (IBD) patients.
- The relationship between IBD, opioid use, and healthcare resource utilization requires further investigation.
Purpose of the Study:
- To analyze real-world data on opioid use patterns in IBD patients.
- To assess the association between opioid use and healthcare resource utilization in IBD.
Main Methods:
- Utilized real-world data from the IBM Watson Health Commercial Claims and Encounters Database (2007-2014).
- Included patients with an initial inflammatory bowel disease (IBD) diagnosis.
- Matched IBD patients with a non-IBD cohort for comparison.
Main Results:
- Opioid use was significantly higher among patients with IBD compared to the matched non-IBD cohort.
- Opioid users, in both IBD cohorts, demonstrated a higher risk of inpatient and emergency room visits, even after adjusting for age, gender, and Charlson Comorbidity Index.
- This suggests a potential link between opioid use and disease severity or control.
Conclusions:
- Opioid use may serve as an indicator of suboptimal inflammatory bowel disease (IBD) control.
- Increased risks of hospitalizations and emergency visits in opioid users highlight the need for improved IBD management strategies.
- Development of a specific outcomes measurement tool for IBD-related pain is recommended.
Keywords:
Crohn’s diseaseIBM Watson Health Commercial Claims and Encounters Databasepain managementulcerative colitisMore Related Videos
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
227
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
227
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
290
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
290
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
01:29Drugs for Treatment of Ulcerative Colitis in IBD
211
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
211